SEC Filings
Atea Pharmaceuticals Borrows $65 Million As Further Loans Hinge On Hepatitis C Milestones
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
SEC Filings
AN2 expects its funds to last into 2029, with enrollment in its global blood-cancer trial expected by year-end.
SEC Filings
The company plans a myasthenia gravis trial in mid-2027, pending regulatory feedback, as it expands beyond thyroid eye disease.
Earnings
The bank raises its full-year loan-loss forecast and expects another write-off tied to the borrower in the fourth quarter.
SEC Filings
Nine-month product sales reached $143.6 million, while the company plans to seek approval for patients not previously treated with BCG.
SEC Filings
The relutrigine team is fully hired, with FDA decisions targeted for December and January.
Earnings
U.S. BRIUMVI sales grew approximately 52% in the third quarter, with new dosing options moving through clinical trials.
SEC Filings
The China study treated 12 patients, with interim results supporting Cullinan’s development plans beyond lupus.
SEC Filings
LISRAYA’s launch raised selling costs, while arthritis, eye-disease and lung-disease trials advanced.
SEC Filings
Insurance access expanded, while commercialization and research spending climbed and operating cash use increased.
SEC Filings
Sherif’s director awards include options on 88,000 shares and restricted stock units covering 28,000 shares.
Deals
The offshore wind installation company owns 92.06% of Cadeler A/S following a share exchange tied to its parent’s move to Britain.